No Love for Big Pharma Heading Into Second Half

There's never really a quiet time in the pharmaceutical business, but the third quarter usually offers a relative respite.

Most of the major medical conferences have been held or won't occur until the fall. The Food and Drug Administration advisory committee calendar for reviewing experimental drugs looks pretty sparse until late September. And there aren't many formal FDA decision dates slated for Big Pharma products in the next few months.

But all's not necessarily quiet behind the scenes. ...